Thermo Fisher Scientific Opens Viral Vector Manufacturing Site in Massachusetts

Thermo Fisher Scientific’s new 300,000 ft² facility, located in Plainville, Mass., will specialize in manufacturing viral vectors.

Thermo Fisher announced the official opening of its new 300,000 ft² facility, located in Plainville, Mass., on Aug. 24, 2022. The new site is designed to support the development, testing, and manufacture of viral vectors.

In addition to its viral vector services, the new site includes translational sciences labs for early-stage development, plasmid DNA manufacturing, cell therapy manufacturing, and integrated commercial packaging and distribution services. Outside of bioproduction and analytical instrumentation technologies, the new site features sustainable construction design, flexible laboratory and production suites, adjacent warehousing, and office space, according to a company press release.

“Plainville is an impressive addition to our pharma services network as we continue to invest and innovate cell and gene therapy services, products and workflows,” said Marc N. Casper, chairman, president, and CEO, Thermo Fisher Scientific, in the release. “We are enabling our customers to speed their scientific discoveries in cell and gene therapy while also supporting their manufacturing needs, whether they are early in the development process or ready to transition to clinical or commercial scale.”

According to the release, the new site will add approximately 300 jobs to the local economy. It is Thermo Fisher Scientific’s sixth viral vector site in the United States and Europe.

Source: Thermo Fisher Scientific